Answers are grounded in this paper and cite their sources.
It is our opinion that biaryl or 'two-ring' mannosides, which represent the largest and most thoroughly tested class of FimH antagonists, also hold the most promise as a novel treatment for UTIs. These antagonists have also been shown to have efficacy in treating CD. Judging from the strong preclinical data, we predict that one or more FimH antagonists will be entering the clinic within the next 1-2 years.
No takes yet. Share an insight, caveat, or question.
Mydock‐McGrane et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: